Observations, lessons, and takeaways from Monday’s failure of Gilead Sciences’ (GILD) NASH drug, selonsertib.
1. In defense of Gilead, a broad swath of Wall Street’s covering analysts argued the negative outcome of the Phase 3 study was expected and therefore already baked into the biotech’s diminished stock price.
About the Author Reprints
cnat future results?
Seems CBAY has been forgotten about in the NASH market, maybe it is a prove it story, but seems worth keeping an eye on since other assets are struggling